NATIONAL HEALTHCARE CORP
At today's price, NATIONAL HEALTHCARE CORP (NHC) is priced for +13.5% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• National HealthCare runs a debt-free balance sheet that is rare in senior care: it carried zero current and long-term debt at the end of the first quarter and held about $258 million in cash and marketable securities, so it owns its operations outright rather than renting them from lenders. [Source: NHC Q1 2026 results] • The biggest specific risk is payor mix: government programs are the core of the revenue, with Medicare alone at 33% of net patient revenue, so a change in Medicare or Medicai
Is NHC overvalued? See what's priced in →
225 institutional managers reported holding NHC in 13F filings for the quarter ended 2026-03-31. Together they hold about 65% of the company; the top 10 hold 49%. 38 opened new positions that quarter. Held by BlackRock, Vanguard Group, Morgan Stanley, among others. On the short side, 553k shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (4.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
NHC's share count grew 1.3% over the past five years even with $57.50M spent on repurchases. It pays a dividend, and has paid one every year in our records (16 and counting), raised 4 years straight; the current rate is $2.53 a share annually. Cash returned over the past three years: $103.69M in dividends and $44.55M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at NHC over the trailing three years: 2023: 2 buys totaling $256k; 2026: 1 buy totaling $175k. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
NHC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2019-02-21 | -0.6% | -12.8% |
| 2020-02-22 | +0.7% | -14.9% |
| 2020-08-08 | +4.8% | -1.2% |
| 2021-02-20 | -1.6% | +9.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
NHC's latest 8-K filings: 2026-07-01 (items 1.01, 1.02, 2.01, 2.03, 7.01, 9.01); 2026-05-27 (items 1.01, 1.02, 2.03, 9.01); 2026-05-15 (items 1.01, 9.01); 2026-05-13 (items 5.07); 2026-05-08 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.